Solution reagent kit Genvinset® HLA DQA1*05

clinicalleadgenomic DNA

Kit for the detection of HLA-DQA1*05 allele by Real-Time PCR technology using TaqMan® probes technology. Information about the product Several studies suggested the role of tumor necrosis factor alpha (TNF) in chronic immune-mediated diseases, such as Crohn’s disease, inflammatory bowel disease (IBD), psoriasis and rheumatoid arthritis. Therefore, anti-TNF therapies were developed and are now the most widely used biological therapies for treating immune-mediated diseases. The most prescribed anti-TNF antibodies are infliximab and adalimumab. Prolonged use of these anti-TNF antibodies may lead to the formation of anti-drug antibodies (ADA), which can decrease the efficacy of these biologics and promote adverse reactions and treatment failure. HLA-DQA1*05 alleles were independently associated with a high risk of infliximab antibody formation in addition to the loss of response and treatment discontinuation. Also, a genome-wide significant association between HLA-DQA1*05 and the development of antibodies against anti-TNF agents was found. Therefore, the screening of the HLA-DQA1*05 allele may be a useful clinical tool that could predict ADA risk and guide the clinical approach of anti-TNF therapies. INTENDED USE Genvinset® HLA DQA1*05 is a semi-automated in vitro diagnostic kit for the qualitative detection of the HLA-DQA1*05 allele in genomic DNA extracted from whole blood, associated with the immunogenicity of anti-TNF drugs, by Real-Time PCR using TaqMan® probes technology. Patients who can benefit from this determination are those referred by a specialist. The results of this test should not be the only ones on which the therapeutic decision is based